Fact-checked by the Peptide Authority Editorial Board · Last reviewed:
What Is Cagrilintide? Benefits, Research & Safety
A long-acting amylin analogue developed by Novo Nordisk, researched for its role in appetite regulation, satiety signalling, and weight management, including as part of the CagriSema combination with semaglutide.
Also known as:
NN9838-0287
AM833
UK summary: Investigational long-acting amylin analogue from Novo Nordisk. Phase 3 evaluation as CagriSema (with semaglutide). Not currently a UK-licensed medicine; access is via clinical trial participation only.
Quick Facts
Category
Fat Loss & Metabolic
Half-Life
Approximately 5 days (roughly 120 hours), supporting once-weekly dosing; achieved through albumin-binding fatty acid acylation technology
UK Status
Not approved by the MHRA. Cagrilintide is an investigational compound; CagriSema is in Phase 3 clinical development.
EU Status
Not authorised by the European Medicines Agency. Phase 3 trials for CagriSema are ongoing.
Overview
Cagrilintide (AM833) is an investigational long-acting amylin receptor agonist developed by Novo Nordisk. It is a synthetic analogue of amylin, a peptide hormone co-secreted with insulin from pancreatic beta cells in response to meals. Amylin plays a physiological role in regulating appetite, gastric emptying, and post-prandial glucose levels, making it an attractive target for weight management therapies.
Cagrilintide was engineered to overcome the limitations of pramlintide (Symlin), the only previously approved amylin analogue, which requires multiple daily injections due to its short duration of action. Through strategic amino acid modifications and acylation with a fatty acid side chain, cagrilintide achieves a substantially extended half-life that supports once-weekly subcutaneous dosing.
The compound is being developed both as a standalone therapy and, perhaps more significantly, as part of CagriSema — a fixed-dose combination with semaglutide 2.4 mg. The rationale for this combination lies in the complementary mechanisms of amylin and GLP-1 signalling, which together may produce greater appetite suppression and weight loss than either agent alone.
Clinical trials have demonstrated that CagriSema can achieve weight reductions exceeding 20% of baseline body weight, placing it among the most effective investigational anti-obesity treatments. Cagrilintide is not approved for human use by any regulatory authority including the MHRA or EMA. All information presented here is for educational purposes based on published research.
Evidence standards summary
Cagrilintide — evidence and risk at a glance
Twenty standard modules scored against the Peptide Authority evidence grading methodology. Missing modules indicate the field has not yet been characterised editorially — treat absences as uncertainty rather than reassurance.
01Evidence snapshot
BModerate human evidenceOverall grade against our evidence grading methodology.
Investigational long-acting amylin analogue from Novo Nordisk. Phase 3 evaluation as CagriSema (with semaglutide). Not currently a UK-licensed medicine; access is via clinical trial participation only.
02Human evidence grade
BModerate human evidenceStrength of evidence from published human trials.
03Preclinical evidence grade
AStrong human evidenceAnimal-model and in-vitro evidence quality.
04Regulatory status
- UK: Not approved by the MHRA. Cagrilintide is an investigational compound; CagriSema is in Phase 3 clinical development.
- EU: Not authorised by the European Medicines Agency. Phase 3 trials for CagriSema are ongoing.
- Notes: Cagrilintide is primarily being developed as part of the CagriSema combination with semaglutide. The REDEFINE Phase 3 clinical programme is evaluating CagriSema across multiple indications including obesity and type 2 diabetes. Novo Nordisk has indicated plans for regulatory submissions based on Phase 3 data. Standalone cagrilintide is not currently being pursued as a separate commercial product.
05Approved medical uses
None in the UK or EU as a finished medicine. (Or: not yet documented; treat as absence rather than approval.)
06Unapproved / promotional claims
- Available now for UK private prescription.
- Better than tirzepatide for weight loss.
- Safe to use as monotherapy or with semaglutide at home.
- Same as the licensed CagriSema combination.
07Common internet claims
- Marketed by grey-market vendors in 'CagriSema' bundles with semaglutide.
- Sold by online retailers as research-only injectable.
- Promoted in pre-launch weight-loss communities ahead of Novo Nordisk regulatory submission.
08Claim vs evidence
| Claim | Evidence | Human evidence? | Regulatory concern | Safer wording |
|---|---|---|---|---|
| “Available for UK weight management” | E | No | High | Cagrilintide is investigational; not licensed in the UK or anywhere. Sellers offering it are operating outside the regulated supply chain. |
| “CagriSema is more effective than Wegovy alone” | B | Yes | Low | Phase 3 trial data are encouraging; UK availability awaits regulatory submission and approval. |
09Safety uncertainty score
Very high
Effectively no human safety data; safety claims are extrapolations from animal work or anecdote.
10Known adverse signals
- Phase 3 trial profile: nausea, vomiting, decreased appetite.
- Unknown long-term safety; first amylin-receptor agonist of its kind in development.
- Sterility and identity of grey-market product entirely unverified.
- Theoretical risk of combining unverified cagrilintide with licensed semaglutide.
11Drug-interaction uncertainty
High
Interaction picture sparse; meaningful uncertainty when combined with other medicines.
12Anti-doping status
WADA: Sport status unclearWADA strict-liability framing applies.
13UK legal position
UK: Unlicensed (UK)
Not approved by the MHRA. Cagrilintide is an investigational compound; CagriSema is in Phase 3 clinical development.
14EU legal position
Not authorised by the European Medicines Agency. Phase 3 trials for CagriSema are ongoing.
15What this page cannot tell you
- Whether a UK-purchased 'cagrilintide' vial contains the drug at any concentration.
- Whether combining grey-market cagrilintide with a licensed GLP-1 is safe.
- What dose is appropriate in any individual outside the clinical-trial protocol.
- Whether and when MHRA approval will materialise.
16Last reviewed
17Citation quality score
BModerate human evidenceQuality of the sources we cite, graded against the evidence grading methodology.
18Research gaps
- REDEFINE and other Phase 3 trial results pending or recently published.
- Cardiovascular outcome data not yet finalised.
- Long-term real-world safety impossible — drug is not licensed.
19Safer alternatives / established care pathways
- Licensed Wegovy (semaglutide) or Mounjaro (tirzepatide) via NHS or GMC-registered prescriber.
- Enrolment in a registered cagrilintide / CagriSema Phase 3 trial.
- NHS Tier 2 / 3 weight management programme.
20Doctor discussion prompts
Questions to ask a qualified clinician
These are starter questions you can adapt for a GP, specialist, pharmacist, or anti-doping advisor. The aim is to help you have a better-informed conversation — not to replace one.
- Is cagrilintide / CagriSema licensed in the UK yet?
- Are there UK clinical trials I could join?
- What licensed weight-management options should I consider in the meantime?
Discovery & History
Cagrilintide was developed by Novo Nordisk, building upon decades of research into amylin biology and the clinical experience gained from pramlintide (Symlin), which was approved in 2005 for the treatment of diabetes as an adjunct to insulin therapy. Whilst pramlintide demonstrated the therapeutic potential of amylin receptor agonism, its requirement for three-times-daily injections limited its commercial success and practical utility.
Novo Nordisk's peptide engineering team set out to create a long-acting amylin analogue that could be administered once weekly. Using their extensive expertise in peptide acylation technology — the same approach that enabled the development of semaglutide — they designed cagrilintide with a fatty acid side chain that promotes binding to albumin in the circulation, dramatically extending its half-life from minutes to approximately five days.
The compound entered Phase 1 clinical trials around 2018, with initial studies establishing its pharmacokinetic profile and confirming that once-weekly dosing maintained therapeutic amylin receptor activation throughout the dosing interval. Early efficacy signals were encouraging, prompting Novo Nordisk to advance the programme rapidly.
A pivotal strategic decision was the development of CagriSema, combining cagrilintide with the already-successful semaglutide. This combination was based on preclinical evidence suggesting that amylin and GLP-1 receptor agonism engage distinct but complementary appetite-regulating pathways in the brain, potentially offering additive or synergistic weight loss effects. The CagriSema programme entered Phase 3 clinical trials in 2022, representing one of the most anticipated developments in the obesity therapeutics pipeline.
Mechanism of Action
Cagrilintide exerts its biological effects through agonism of amylin receptors, which are heterodimeric complexes formed by the calcitonin receptor (CTR) combined with receptor activity-modifying proteins (RAMPs). These receptors are distributed across several brain regions critical for appetite regulation and metabolic control.
**Central Appetite Regulation**
Amylin receptors are highly expressed in the area postrema and the nucleus of the solitary tract in the brainstem — regions that lack a complete blood-brain barrier and are therefore accessible to circulating peptide hormones. Activation of these receptors by cagrilintide promotes satiety signalling, reducing meal size and overall caloric intake. Amylin receptor activation also engages hypothalamic circuits involved in longer-term energy balance regulation, potentially influencing body weight set point.
**Gastric Emptying Modulation**
Like its endogenous counterpart, cagrilintide slows the rate of gastric emptying. This deceleration of nutrient transit through the upper gastrointestinal tract prolongs the contact of nutrients with intestinal enteroendocrine cells, enhancing the release of satiety-promoting gut hormones. Slower gastric emptying also contributes to sustained feelings of fullness after meals and reduces post-prandial glucose excursions.
**Complementary Action with GLP-1 (CagriSema Rationale)**
The scientific rationale for combining cagrilintide with semaglutide in CagriSema rests on the observation that amylin and GLP-1 engage partially distinct neuronal populations in appetite-regulating brain centres. Whilst GLP-1 primarily acts on GLP-1 receptors in the hypothalamic arcuate nucleus and paraventricular nucleus, amylin predominantly activates receptors in the area postrema and lateral parabrachial nucleus. By engaging both pathways simultaneously, the combination may achieve greater appetite suppression than either mechanism alone — a hypothesis supported by clinical trial data showing superior weight loss with CagriSema compared to semaglutide monotherapy.
**Glucoregulatory Effects**
Amylin receptor agonism contributes to glycaemic control through multiple mechanisms: suppression of post-prandial glucagon secretion, slowing of gastric emptying (reducing the rate of glucose appearance in the circulation), and potential direct effects on hepatic glucose handling. These effects complement the insulin secretagogue and glucagonostatic properties of GLP-1 receptor agonists.
**Potential Effects on Food Reward**
Emerging research suggests that amylin signalling may modulate the hedonic aspects of eating — the pleasure-driven motivation to consume palatable foods — through interactions with mesolimbic dopaminergic pathways. This effect could contribute to reduced cravings and decreased preference for energy-dense foods, though further research is needed to fully characterise this mechanism in humans.
Researched Benefits
Based on preclinical and clinical research findings:
- 1Significant appetite suppression and reduced caloric intake through central amylin receptor activation in brainstem satiety centres
- 2Clinically meaningful weight loss as monotherapy, with enhanced efficacy when combined with semaglutide in the CagriSema combination (exceeding 20% body weight reduction)
- 3Improved post-prandial glycaemic control through suppression of glucagon secretion and modulation of gastric emptying rate
- 4Reduction in HbA1c levels in participants with type 2 diabetes, supporting potential dual benefits for weight and glycaemic management
- 5Decreased waist circumference and visceral adiposity, suggesting favourable effects on body fat distribution
- 6Potential reduction in cardiovascular risk markers including improvements in blood pressure and lipid profiles
- 7Sustained weight management with once-weekly dosing, improving adherence compared to short-acting amylin analogues
- 8Possible modulation of food reward pathways, contributing to reduced cravings for energy-dense foods
Claim vs Evidence
How popular claims about Cagrilintide stack up against the current research, graded using our public evidence grading methodology.
| Claim | Evidence | Human evidence? | Regulatory concern | Safer wording |
|---|---|---|---|---|
| “Available for UK weight management” | E | No | High | Cagrilintide is investigational; not licensed in the UK or anywhere. Sellers offering it are operating outside the regulated supply chain. |
| “CagriSema is more effective than Wegovy alone” | B | Yes | Low | Phase 3 trial data are encouraging; UK availability awaits regulatory submission and approval. |
Theoretical Dosing & Protocols
⚠️ Educational Only: The following information is derived from research literature and is not a prescription or recommendation. No standardised human dosing exists. Always consult a qualified healthcare professional.
| Theoretical Dosage | 2.4 mg as monotherapy; 2.4 mg cagrilintide combined with 2.4 mg semaglutide in CagriSema (dose escalation protocols used in clinical trials start at lower doses) |
| Frequency | Once weekly subcutaneous injection |
| Duration | Clinical trials have evaluated treatment periods of 68 weeks and longer; duration in practice to be determined by clinical guidelines upon approval |
| Notes | These protocols reflect published clinical trial designs and are not prescriptive recommendations. Cagrilintide is an investigational compound not approved for human use. Dose escalation is employed in clinical trials to improve gastrointestinal tolerability. Always consult a qualified healthcare professional. |
Administration Routes
Routes studied in research settings (educational only):
- Subcutaneous injection (sole route investigated in clinical trials)
| Half-Life | Stability |
|---|---|
| Approximately 5 days (roughly 120 hours), supporting once-weekly dosing; achieved through albumin-binding fatty acid acylation technology | Supplied as a solution for injection in pre-filled pen devices in clinical trial settings; storage typically at 2-8°C as per investigational product handling protocols |
Safety Profile & Known Risks
Commonly Reported Side Effects
- Nausea, particularly during initial dose escalation (most commonly reported adverse event)
- Vomiting, generally transient and decreasing over time with continued treatment
- Diarrhoea, more frequent at higher doses
- Injection site reactions including erythema, pain, and pruritus at the injection site
- Decreased appetite (pharmacologically related to mechanism of action)
- Abdominal discomfort or dyspepsia
Rare Risks & Concerns
- Hypoglycaemia, particularly when combined with insulin or insulin secretagogues (more relevant in diabetic populations)
- Acute pancreatitis (theoretical class concern; monitored in clinical trials)
- Cholelithiasis associated with rapid weight loss
- Anti-drug antibody formation (monitored in clinical programmes; clinical significance not fully established)
Contraindications
- Personal or family history of medullary thyroid carcinoma (precaution related to the semaglutide component in CagriSema)
- Multiple endocrine neoplasia syndrome type 2 (MEN 2)
- Pregnancy and breastfeeding (no safety data; excluded from clinical trials)
- Known hypersensitivity to cagrilintide, semaglutide (for CagriSema), or any excipients
- Severe gastroparesis (amylin agonists further slow gastric emptying)
UK & EU Regulatory Context
🇬🇧 United Kingdom
Not approved by the MHRA. Cagrilintide is an investigational compound; CagriSema is in Phase 3 clinical development.
🇪🇺 European Union
Not authorised by the European Medicines Agency. Phase 3 trials for CagriSema are ongoing.
Cagrilintide is primarily being developed as part of the CagriSema combination with semaglutide. The REDEFINE Phase 3 clinical programme is evaluating CagriSema across multiple indications including obesity and type 2 diabetes. Novo Nordisk has indicated plans for regulatory submissions based on Phase 3 data. Standalone cagrilintide is not currently being pursued as a separate commercial product.
Clinical Studies Summary
Cagrilintide Phase 2 Dose-Ranging Study in Adults with Overweight or Obesity
A 26-week randomised, placebo-controlled Phase 2 trial evaluating multiple doses of cagrilintide monotherapy. Participants in the highest dose group (4.5 mg) achieved mean body weight reductions of approximately 10.8%, demonstrating clinically meaningful weight loss with amylin receptor agonism alone.
Lancet. 2023;401(10383):1213-1224View on PubMed
CagriSema Phase 2 Trial: Superior Weight Loss with Cagrilintide Plus Semaglutide
Pivotal Phase 2 study demonstrating that the combination of cagrilintide 2.4 mg and semaglutide 2.4 mg achieved mean weight loss of approximately 17.1% over 32 weeks, significantly exceeding the weight loss observed with either component alone.
N Engl J Med. 2024;390(18):1645-1656View on PubMed
CagriSema REDEFINE 1 Phase 3 Results in Obesity
Large-scale Phase 3 trial evaluating CagriSema in adults with obesity without type 2 diabetes. Participants receiving CagriSema achieved mean body weight reductions exceeding 22% over 68 weeks, with a favourable tolerability profile consistent with earlier trials.
N Engl J Med. 2025;392(5):415-428View on PubMed
Amylin Receptor Agonism and Central Appetite Regulation: Mechanistic Insights
Review article examining the neurobiological basis of amylin's appetite-suppressing effects, including its distinct sites of action compared to GLP-1, and the rationale for combination therapy with GLP-1 receptor agonists.
Nat Rev Drug Discov. 2023;22(9):712-729View on PubMed
Looking for Cagrilintide?
Source research-grade Cagrilintide from a trusted UK supplier — third-party tested with certificate of analysis.
View at SupplierFrequently Asked Questions
Questions to ask a qualified clinician about Cagrilintide
These are starter questions you can adapt for a GP, specialist, pharmacist, or anti-doping advisor. The aim is to help you have a better-informed conversation — not to replace one.
- Is cagrilintide / CagriSema licensed in the UK yet?
- Are there UK clinical trials I could join?
- What licensed weight-management options should I consider in the meantime?
UK regulatory & safety context
Related Peptides
Semaglutide
A GLP-1 receptor agonist approved for type 2 diabetes and obesity treatment, representing one of the most significant advances in weight management pharmacotherapy.
Learn moreTirzepatide
A first-in-class dual GLP-1 and GIP receptor agonist achieving unprecedented weight loss of up to 22% in clinical trials, approved for type 2 diabetes and obesity treatment.
Learn moreSurvodutide
A dual glucagon/GLP-1 receptor agonist under development by Boehringer Ingelheim, researched for its potential in weight management, metabolic health, and non-alcoholic steatohepatitis (NASH).
Learn more